Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of...
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.17 | -10.6918238994 | 1.59 | 1.59 | 1.3225 | 430587 | 1.40314951 | CS |
4 | 0.24 | 20.3389830508 | 1.18 | 1.8 | 1.17 | 815068 | 1.50130049 | CS |
12 | 0.5869 | 70.4477253631 | 0.8331 | 1.8 | 0.7202 | 768072 | 1.19013293 | CS |
26 | 0.49 | 52.688172043 | 0.93 | 1.8 | 0.63 | 827480 | 0.99683398 | CS |
52 | -1.03 | -42.0408163265 | 2.45 | 2.5 | 0.63 | 569914 | 1.18601977 | CS |
156 | -6.425 | -81.8992989165 | 7.845 | 9.72 | 0.63 | 281705 | 2.31309944 | CS |
260 | -40.6 | -96.6206568301 | 42.02 | 63.62 | 0.63 | 251160 | 6.02088408 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관